Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I/II Clinical Trial of Topical KB105, a Replication-incompetent, Non-integrating HSV-1 Vector Expressing Human Transglutaminase 1 (TGM1) for the Treatment of TGM1-deficient Autosomal Recessive Congenital Ichthyosis (ARCI)

Next Previous
Search
Trial Profile

A Phase I/II Clinical Trial of Topical KB105, a Replication-incompetent, Non-integrating HSV-1 Vector Expressing Human Transglutaminase 1 (TGM1) for the Treatment of TGM1-deficient Autosomal Recessive Congenital Ichthyosis (ARCI)

Status: Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 12 Nov 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Inetagugene geperpavec (Primary)
  • Indications Ichthyosis
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Acronyms GEM-3
  • Sponsors Krystal Biotech

    • Most Recent Events

    • 07 Nov 2022 According to a Krystal Biotech media release, dosing the next cohort is on track to resume in early 2023.
    • 08 Aug 2022 According to a Krystal Biotech media release, dosing the next cohort is on track to resume in 2H 2022.
    • 10 Sep 2021 Planned primary completion date changed from 1 Mar 2020 to 1 Oct 2022.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top